Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.773 USD | -5.39% | -9.34% | -17.95% |
Financials (USD)
Sales 2024 * | 2.8M | Sales 2025 * | 4M | Capitalization | 59.48M |
---|---|---|---|---|---|
Net income 2024 * | -101M | Net income 2025 * | -109M | EV / Sales 2024 * | 21.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.9 x |
P/E ratio 2024 * |
-0.6
x | P/E ratio 2025 * |
-0.65
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.19% |
Latest transcript on Kezar Life Sciences, Inc.
1 day | -5.39% | ||
1 week | -9.34% | ||
Current month | -5.72% | ||
1 month | -2.84% | ||
3 months | -11.67% | ||
6 months | +8.36% | ||
Current year | -17.95% |
Managers | Title | Age | Since |
---|---|---|---|
Christopher Kirk
FOU | Founder | 52 | 15-02-18 |
John Fowler
FOU | Founder | 52 | 15-02-18 |
Marc Belsky
DFI | Director of Finance/CFO | 68 | 18-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 16-10-31 |
Graham Cooper
CHM | Chairman | 54 | 17-09-30 |
Michael Kauffman
BRD | Director/Board Member | 60 | 16-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.7784 | -4.72% | 742 661 |
24-05-09 | 0.817 | -0.49% | 669,717 |
24-05-08 | 0.821 | -2.26% | 620,204 |
24-05-07 | 0.84 | +3.11% | 453,290 |
24-05-06 | 0.8147 | -4.98% | 497,544 |
Delayed Quote Nasdaq, May 10, 2024 at 02:43 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.95% | 59.48M | |
+3.75% | 108B | |
+11.13% | 104B | |
+1.28% | 22.33B | |
-12.79% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.69% | 17.64B | |
+3.72% | 14.05B | |
+37.33% | 12.51B |
- Stock Market
- Equities
- KZR Stock